Clinical Trial Update: TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update for TP04HN106 in amyotrophic lateral sclerosis, a Phase 1/Phase 2 study that is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• TP04HN106

Snippet

Sponsor: Talengen Institute of Life Sciences, Shenzhen, P.R. China. | Conditions: Amyotrophic Lateral Sclerosis | Phase 1, Phase 2 | Status: RECRUITING